AdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214 in development for fibrotic diseases, including the debilitating and fatal disease Idiopathic Pulmonary Fibrosis. …
AdAlta announces positive results from Phase 1 extension study of lead asset AD-214
March 6, 2024 Australian Biotech
Latest Video
New Stories
-
NZ Government appoints former Deputy PM new chair of Pharmac
April 29, 2024 - - Latest News -
The listing will 'benefit thousands of Australian women', says Mark Butler
April 29, 2024 - - Latest News -
'An important first step to achieving reimbursed access for eligible patients in Australia'
April 28, 2024 - - Latest News -
The 'Week in Review' Podcast - 26 April
April 28, 2024 - - Podcast -
New research shows adult vaccination programs deliver major return on investment
April 26, 2024 - - Latest News -
Productivity Commission research backs the benefit of faster access to medicines
April 26, 2024 - - Latest News -
Let's make decisions based on credible information and not guesswork
April 24, 2024 - - Latest News